PEOPLE - Nuvelo makes appointment:
This article was originally published in Clinica
Nuvelo, previously Hyseq Pharmaceuticals, has elected Burton Sobel to its board of directors, effective immediately. Dr Sobel - a professor at the University of Vermont - succeeds Philippe Chambon, who resigned recently. The Sunnyvale, California-based firm, which focuses on cardiovascular products and acute peripheral arterial and catheter occlusion, merged with Variagenics in January 2003 (see Clinica No 1043, p 14).
You may also be interested in...
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.
Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.